跳转至内容
Merck
所有图片(1)

Key Documents

SML3203

Sigma-Aldrich

Tebipenem

≥98% (HPLC)

别名:

(1R,5S,6S)-2-[1-(1,3-Thiazolin-2-yl)azetidin-3-yl]thio-6-[(R)-1-hydroxyeth yl]-1-methyl-carbapen-2-em-3-carboxylic acid, (4R,5S,6S)-3-[[1-(4,5-Dihydro-2-thiazolyl)-3-azetidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, L-084 active drug, LJC 11,036, LJC 11036, ME1211 active drug, SPR 859, SPR 994 active drug, SPR-859, SPR-994 active drug, SPR859, SPR994 active drug, TBM, TBM-PI active drug, Tebi-pivoxil active drug, [4R-[4α,5β,6β(R*)]]-3-[[1-(4,5-Dihydro-2-thiazolyl)-3-azetidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C16H21N3O4S2
分子量:
383.49
MDL號碼:
分類程式碼代碼:
51111800
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

−20°C

InChI

1S/C16H21N3O4S2/c1-7-11-10(8(2)20)14(21)19(11)12(15(22)23)13(7)25-9-5-18(6-9)16-17-3-4-24-16/h7-11,20H,3-6H2,1-2H3,(H,22,23)/t7-,8-,10-,11-/m1/s1

InChI 密鑰

GXXLUDOKHXEFBQ-YJFSRANCSA-N

生化/生理作用

Tebipenem (LJC 11,036; SPR859; TBM) is a carbapenem class broad-spectrum β-lactam antibiotic against both gram-positive and gram-negative bacteria, including penicillin-resistant S. pneumoniae (PRSP) and many β-lactamase-producing strains (respective MIC ≤6-200 and ≤25-390 ng/mL), while being less effective against methicillin-resistant S. aureus (MRSA), S. marcescens, and P. aeruginosa (respective MIC ranges 0.2 to12.5, 0.05 to100, 3.13 to >100 μg/mL). TBM is 2- to 64-fold more potent than imipenem, cefdinir, and faropenem against clinical isolates from respiratory and urinary-tract infections.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Aileen Rubio et al.
ACS infectious diseases, 4(10), 1436-1438 (2018-08-18)
Carbapenems are potent antibacterials with broad-spectrum activity. However, poor oral absorption generally confines this important drug class to in-hospital use by intravenous (IV) administration. The continued rise in drug resistant pathogens creates a need for alternative oral therapies with broad-spectrum
Visanu Thamlikitkul et al.
Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 97(12), 1259-1268 (2015-03-15)
To determine in vitro and in vivo activity of tebipenem against ESBL-producing E. coli. Minimum inhibitory concentration (MIC) of tebipenem against 100 clinical isolates of ESBL-producing E. coli was performed by broth micro-dilution technique. Blood and urine samples from 10

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门